New USPTO patent regulations may foster more litigation
One of the goals of the America Invents Act (AIA) was to cut down on the number of patent litigation cases being filed. But recently released regulations by the USPTO may do just the opposite. Bookmark on DeliciousDigg this postRecommend on Facebookshare via RedditShare with StumblersTweet about itSubscribe to the comments on this post
Four important things to know as the America Invents Act goes into effect
Much will change in the patent management world as the America Invents Act takes effect. Here’s a list of 4 important changes to keep in mind: File Early and Often. Since the Act changes the U.S. patent system from a first-to-invent to a first-to file, inventors will need “to race to the U.S. Patent and [...]
Will patent reform serve to attract the capital required to improve IP values and stimulate innovation?
Glenn D. Sacks, CPA, of Marks Paneth & Shron LLP, writes the changes in patent law being ushered in by America Invents Act will work to increase the value of patent portfolios and create a system which spawns and nourishes innovation. Here’s how he sees it working: Bookmark on DeliciousDigg this postRecommend on Facebookshare via [...]
Patent reform will put a budget strain on university technology transfer offices
In an interview in Newlogic, Inc, Melba Kurman, president of Triple Helix Innovation, stated America Invents Act’s world-conforming “first-to-file” change will significantly impact the technology transfer processes and budgets in most universities. Bookmark on DeliciousDigg this postRecommend on Facebookshare via RedditShare with StumblersTweet about itSubscribe to the comments on this post
USPTO seeking comments on American Invents Act
The U.S. Patent and Trademark Office has made three proposed changes to the rules of the Leahy-Smith America Invents Act (AIA), which changes the U.S. patent system from a first-to-invent to a first-to-file system. (Search AIA at ipvalue-site.com). The agency is seeking comments on the changes, notes Travis Stanford of courthouse news.com. Public comment is due [...]
What developments in 2011 most affected university technology transfer?
Melba Kurman writes in Innovation Excellence her list of the top five events that affected university technology transfer in 2011. Top on her list, and most others, is AIA, the America Invents Act. According to her research, universities are typically late to file for patents and slow to use the provisional patent tool, each a [...]
Politics may determine the fate of SBIR and STTR innovation funding programs
Early this month, the U.S. Senate approved a bill reauthorizing the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. SBIR is the largest federal research program for small businesses; STTR targets university start-ups. Bookmark on DeliciousDigg this postRecommend on Facebookshare via RedditShare with StumblersTweet about itSubscribe to the comments on this [...]
USPTO moving to improve collection of patent assignment data
In a positive move for analysts and patent owners alike, the USPTO is considering developing a more complete record of assigned patents and applications. Bookmark on DeliciousDigg this postRecommend on Facebookshare via RedditShare with StumblersTweet about itSubscribe to the comments on this post
Healthcare intangibles may face a new round of impairment testing
Accounting Standard Codification 350 – Intangibles, Goodwill and Other Indefinite Lived Assets governs the accounting treatment for goodwill and indefinite-lived intangible assets previously accounted for in a business combination, and increased M&A in healthcare has served to focus more attention on the intangible assets recognized on companies’ financial statements. In the opinion of Andrew Galbraith, [...]
CBO report supports cost savings nature of the Preserve Access to Affordable Generic Drugs Act
Just as the Pfizer/Ranbaxy agreement that delayed the introduction of generic Lipitor winds to a close, the Preserve Access to Affordable Generic Drugs Act (S.27) has been referred out of committee. The bill is specifically designed to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug [...]
Share your thoughts...